{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T07:45:02Z","timestamp":1722930302463},"reference-count":43,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2015,8,26]],"date-time":"2015-08-26T00:00:00Z","timestamp":1440547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008220","name":"Canadian Foundation for AIDS Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008220","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP\u201079529"],"award-info":[{"award-number":["MOP\u201079529"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Fibroblast\u00a0growth\u00a0factor\u00a023\u00a0(<jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>23) has been associated with cardiovascular mortality. We estimate associations between the level of plasma <jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>23 and exposure to abacavir (<jats:styled-content style=\"fixed-case\">ABC<\/jats:styled-content>) and to other components of antiretroviral therapy in patients co\u2010infected with <jats:styled-content style=\"fixed-case\">HIV<\/jats:styled-content> and hepatitis C.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Both intact and c\u2010terminal <jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>23 were measured in plasma using commercial assays for a sub\u2010cohort of 295 patients selected at random from the 1150 patients enrolled in the Canadian Co\u2010infection Cohort. The multiplicative effects of antiretroviral drug exposures and covariates on median <jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>23 were then estimated using a hierarchical Bayesian model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median level of intact <jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>23 was independent of either past or recent exposure to abacavir, with multiplicative ratios of 1.00 and 1.07, 95% credible intervals 0.90\u20131.12 and 0.94\u20131.23, respectively. Median intact <jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>23 tended to increase with past use of both nonnucleoside reverse\u2010transcriptase inhibitors and protease inhibitors, but tended to decrease with recent use of either tenofovir, efavirenz or lopinavir. There were no obvious associations between the median level of c\u2010terminal <jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>23 and individual drugs or drug classes. Age, female gender, smoking and the aspartate aminotransferase to platelet ratio index were all associated with a higher median c\u2010terminal <jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>23 but not with a higher median intact <jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>23.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The level of <jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>23 in plasma was independent of exposure to <jats:styled-content style=\"fixed-case\">ABC<\/jats:styled-content>. Lower levels of intact <jats:styled-content style=\"fixed-case\">FGF<\/jats:styled-content>23 with recent use of tenofovir, efavirenz or lopinavir may reflect their adverse effects on bone and vitamin D metabolism relative to other drugs in their respective drug classes.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.12305","type":"journal-article","created":{"date-parts":[[2015,8,26]],"date-time":"2015-08-26T10:29:46Z","timestamp":1440584986000},"page":"373-379","source":"Crossref","is-referenced-by-count":4,"title":["Fibroblast growth factor 23: associations with antiretroviral therapy in patients co\u2010infected with <scp>HIV<\/scp> and hepatitis C"],"prefix":"10.1111","volume":"17","author":[{"given":"J","family":"Young","sequence":"first","affiliation":[{"name":"Department of Medicine Division of Infectious Diseases\/Chronic Viral Illness Service McGill University Health Centre Montreal QC Canada"},{"name":"Basel Institute for Clinical Epidemiology and Biostatistics University Hospital Basel Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Mucsi","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Nephrology McGill University Health Centre Montreal QC Canada"},{"name":"Department of Medicine Division of Nephrology University Health Network University of Toronto Toronto ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KC","family":"Rollet\u2010Kurhajec","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Infectious Diseases\/Chronic Viral Illness Service McGill University Health Centre Montreal QC Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MB","family":"Klein","sequence":"additional","affiliation":[{"name":"Department of Medicine Division of Infectious Diseases\/Chronic Viral Illness Service McGill University Health Centre Montreal QC Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Canadian Co\u2010infection Cohort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,8,26]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV\u20101\u2010infected adults and adolescents.http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adultandadolescentgl.pdf1 May 2014 (accessed 10 June 2014)."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000662"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfs259"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.02740311"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.03.040"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46122"},{"key":"e_1_2_7_8_1","doi-asserted-by":"crossref","unstructured":"PateinakisP PapagianniA.Fibroblast growth factor\u201023 and adverse clinical outcomes in chronic kidney disease patients. 1 April 2013. Available athttps:\/\/www.oapublishinglondon.com\/article\/481(accessed 30 April 2014).","DOI":"10.13172\/2053-0293-1-1-481"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.3"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq066"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2012.07.002"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis306"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32836010dd"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2010.526602"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.176"},{"key":"e_1_2_7_16_1","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1177\/135965350701200701","article-title":"The association of bone mineral density with HIV infection and antiretroviral treatment in women","volume":"12","author":"Anastos K","year":"2007","journal-title":"Antivir Ther"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283262a64"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833c3281"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032445"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01096-13"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-010-0071-3"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.110.957415"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2012.02953.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2724"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyp297"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/0004563213510708"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2013-0208"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60423-7"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7039.1153"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)60595-9"},{"key":"e_1_2_7_31_1","first-page":"591","volume-title":"Appendix C: Example of Computation in R and Bugs","author":"Gelman A","year":"2003"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2008.07.015"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.00915.x"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1214\/06-BA117A"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt264"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1310\/hct1405-224"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2755"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834544af"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32834542fa"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32832c4947"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32835192ae"},{"key":"e_1_2_7_42_1","unstructured":"BrownT MoserC CurrierJet\u00a0al.Bone density changes after antiretroviral initiation with protease inhibitors or raltegravir.http:\/\/croiconference.org\/sites\/all\/abstracts\/779LB.pdf3 March 2014 (accessed 28 October 2014)."},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058961"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mnh.0000447020.74593.6f"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fhiv.12305","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.12305","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:52:40Z","timestamp":1695574360000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.12305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,26]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["10.1111\/hiv.12305"],"URL":"https:\/\/doi.org\/10.1111\/hiv.12305","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"type":"print","value":"1464-2662"},{"type":"electronic","value":"1468-1293"}],"subject":[],"published":{"date-parts":[[2015,8,26]]}}}